TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02183792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study: NCT03093974

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
Study: NCT01724086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
Study: NCT01486992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI+Nimotuzumab
Description: irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
Study: NCT01852591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 13
Study: NCT02030457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI
Description: Breath Activated Inhaler (BAI)
Study: NCT03672032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fork-tip Needle
Description: Fork-tip Needle will be used to obtain biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Franseen Needle
Description: Franseen Needle will be used to obtain biopsy
Study: NCT01078272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Remote Ischemic Preconditioning
Description: Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
Study: NCT03223688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day-Care early intervention program
Description: The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPD+SI intervention program
Description: The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OPD intervention program
Description: The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
Study: NCT03696056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation
Description: The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music listening program
Description: The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log.
Study: NCT05247307

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: convalescent plasma infusion covid 19
Description: Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: convalescent plasma infusion covid 19
Description: Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts.
Study: NCT01064609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy by cryoprobes
Description: Transbronchial lung biopsy with cryoprobes.
Study: NCT02085525

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Practitioner Clinic
Description: The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs.

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Practitioner Clinic
Description: The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs.
Study: NCT03407378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPT803
Description: Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPT803
Description: Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optional pharmacogenetic assessment
Description: Blood sample of 3 milliliters for genotyping assessment (according to patient consent).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optional pharmacogenetic assessment
Description: Blood sample of 3 milliliters for genotyping assessment (according to patient consent).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional Blood-Oxygen-level Dependent functionalMRI
Description: BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional Blood-Oxygen-level Dependent functionalMRI
Description: BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Assessments before taking regular PD treatment
Description: Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Assessments on regular PD treatment
Description: Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
Study: NCT00421538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nadroparine calcium
Description: Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
Study: NCT02606435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention (PCI)
Description: percutaneous coronary intervention (PCI) by stent implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention (PCI)
Description: percutaneous coronary intervention (PCI) by stent implantation
Study: NCT02030457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI
Description: Breath Activated Inhaler (BAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI
Description: Breath Activated Inhaler (BAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate MDI
Description: Metered Dose Inhaler (MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate MDI
Description: Metered Dose Inhaler (MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate MDI
Description: Metered Dose Inhaler (MDI)
Study: NCT04337203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARE-S Implementation Program
Description: The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
Study: NCT04737551

Intervention type: OTHER
Intervention: Follow-up only
Description: Only routine follow-up but no treatment

Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.

Intervention type: RADIATION
Intervention: Adjuvant chemoradiotherapy
Description: Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion.
Study: NCT02606435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombus aspiration
Description: thrombus aspiration with export catheter
Study: NCT04333940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periapical surgery
Description: clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery
Description: clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
Study: NCT06416176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) Program
Description: Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
Study: NCT03109262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: As part of PET/CT and SPECT/CT scans.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: As part of PET/CT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 90-Yttrium (Y-90) Glass Microspheres
Description: Radiolabel for PET/CT scan
Study: NCT01724086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
Study: NCT03109262

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Technetium 99mTc albumin aggregated (99mTc-MAA)
Description: Radiolabel for 99mTc-MAA SPECT/CT Scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-photon emission computerized tomography (SPECT) scan
Description: As part of SPECT/CT scan
Study: NCT02133664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoic acid and omega-3 fatty acids
Description: alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lipoic acid and placebo oil
Study: NCT03789695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate
Description: Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
Study: NCT02815436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone reminder
Description: a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminder
Description: a one-way, SMS message sent from the centre to the screening participant's mobile phone
Study: NCT00003787

Intervention type: BEHAVIORAL
Intervention: educational/counseling intervention

Intervention type: BEHAVIORAL
Intervention: therapeutic dietary intervention

Intervention type: BEHAVIORAL
Intervention: therapeutic dietary intervention
Study: NCT04054492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-IPV+bOPV+bOPV
Description: 202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV+Sabin-IPV+bOPV
Description: 197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV+Sabin-IPV+Sabin-IPV
Description: 205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
Study: NCT04737551

Intervention type: RADIATION
Intervention: Adjuvant chemoradiotherapy + Adjuvant chemotherapy
Description: See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
Study: NCT02194192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondasetron 8 mg IV after spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine 10 mg IV after spinal anesthesia
Study: NCT01431456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Nadroparin
Study: NCT00989664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation.
Study: NCT03479203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette Aerosol
Description: 16 two-second-long puffs from a non-nicotinized electronic cigarette.
Study: NCT03194672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Adolescent Transitions (HAT) program
Description: The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities.
Study: NCT01414439

Intervention type: BEHAVIORAL
Intervention: Existential Group Therapy
Description: The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
Study: NCT04557696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REFLECT Curriculum
Description: Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
Study: NCT01587599

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling
Description: The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: counseling
Description: The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
Study: NCT02966106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right prefrontal low frequency rTMS
Description: A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham-rTMS
Description: Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
Study: NCT03390127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.